Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The NLRP1 gene is 96 Kb in length and contains 49 exons. Its encoded protein is a member of the NLR family of nucleotide oligomeric domain-like receptors and contains a set of cytoplasmic pattern recognition receptors, which are rich in leucine repeats (LRR) and are capable of non-specific recognition of microbial surface molecules, thereby activating innate immunity. The NLRP1 signaling pathway is mainly composed of the receptor NLRP1, the adaptor protein ASC and the effector protein caspase-1.
Figure 1. Mechanisms of NLRP1-Mediated Autoinflammatory Disease in Humans and Mice. (Yu, C. H., et al. 2017)
Biological Function of NLRP1
The main activating substances of NLRP1 inflammasome have been found to include: muramyl dipeptide (MDP), anthrax lethal toxin (LT), and parasites such as Toxoplasma gondii, which are found in almost all bacteria. NLRP1 is widely present in T cells, B cells, monocytes, macrophages, dendritic cells, and granulocytes. NLRP1 inflammasome promotes the maturation of IL-1β, IL-18 and IL-33, and plays an important role in the inflammatory response and anti-infection of human body. IL-1β promotes inflammatory responses such as leukocyte infiltration, lymphocyte activation, acute phase protein induction, and fever. It binds to the IL-1β receptor and induces the secretion of a large number of inflammatory and chemokines.
There is an inhibitory regulation of the NLRP1 inflammasome in the normal body, so that the activation of the inflammasome is in a strict regulation. The currently known negative regulation pathways of NLRP1 inflammasome are as follows: (1) Self-inhibition: The NACHT domain interacts with the LRR domain to inhibit self-activation. (2) Proteins containing a CARD domain: For example, a single CARD protein, an inhibitory CARD protein, Caspase-12, etc. interfere with the assembly of Caspase-1 in an inflammatory body. (3) Proteins containing a PYD domain: for example, heat shock proteins interfere with the interaction of ASC with NLRP1. (4) Anti-apoptotic proteins: For example, Bcl-2 and Bcl-XL interact with the NACHT-LRR domain of NLRP1 to inhibit the activation of Caspase-1. (5) Viral proteins: For example, Kaposi's sarcoma virus, herpes virus and the like can bind to NLRP1 and other NLR family proteins to inhibit the activation of inflammatory bodies.
NLRP1 Inflammatory Body and Disease
By detecting the mRNA levels of TNF-α and monocytes in patients, it was found that the NLRP1 inflammasome mRNA content changed significantly in the early stage of infection, and the change of this content was positively correlated with the survival of patients: surviving infected patients The amount of NLRP1 expressed was higher than that of the deceased. Anthrax is caused by the invasion of Bacillus anthracis. The release of LT from Bacillus anthracis can induce an NLRP1-dependent immune response in mice, enhance lysosomal membrane permeability, release cytoplasmic cathepsin, and mediate cell pyroptosis. In the process of Toxoplasma infection, NLRP1 inflammasome affects the susceptibility and immune response of congenital toxoplasmosis in humans. RNA interference with NLRP1 expression results in a dull immune response to Toxoplasma infection by monocytes, which accelerates the death and lysis of infected cells. All of this indicates that NLRP1 is an important component of the innate immune response and plays an important role in the clearance of pathogenic bacteria. On the other hand, the study found that LT can activate the macrophage NLRP1 inflammatory body and Caspase-1, which cause LT-sensitive macrophage lysis and animal death after B. anthracis infection. This illustrates the complexity of the role of NLRP1 inflammasome in immune infections.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.